Join our community of smart investors

GSK beats Q2 forecasts

Revenues landed ahead of consensus expectations, helped by vaccine and pharma sales
July 28, 2021

 

  • The FTSE 100 pharma giant explained its consumer demerger plans last month
  • It will continue to invest in its drug pipeline this year

GlaxoSmithKline (GSK) did not have an easy ride into Wednesday’s half-year numbers. The FTSE 100 pharma giant has faced pressure in recent months to explain how it will demerge its consumer healthcare business, what the future growth plans are for its whittled-down biopharma business and how those ambitions will affect its financial statements. As reported by the Financial Times in April, activist investor Elliott Management has built a multi-billion pound stake in the company.

This is subscriber only content
Start your trial to keep reading
PRINT AND DIGITAL trial

Get 12 weeks for £12
  • Essential access to the website and app
  • Magazine delivered every week
  • Investment ideas, tools and analysis
Have an account? Sign in